The nebulized formulations of IVT-mRNA-encoding alpha-1-antitrypsin (A1AT-mRNA) would be a highly acceptable and tolerable remedy for the protein replacement therapy for alpha-1-antitrypsin deficiency in the future. This evidence concerns the gene SERPINA1 and hyperinsulinemic hypoglycemia, familial, 4.